Soleo Health Selected as a Specialty Pharmacy Partner of RYPLAZIM® for Plasminogen Deficiency Type 1 (PLGD-1) Treatment
May 06 2024 - 6:00AM
Business Wire
Company Selected Based on its Specialty
Pharmacy Capabilities in Treating Patients with Ultra-rare
Diseases
Soleo Health, an innovative leader and national provider of
complex specialty pharmacy services for treating rare- and
ultra-rare diseases, announced today it has been named a limited
distribution specialty pharmacy partner to dispense RYPLAZIM®
(plasminogen, human-tvmh), manufactured by Kedrion Biopharma.
RYPLAZIM is the first and only Food & Drug Administration
(FDA)-approved treatment for supporting the approximately 500
people in the U.S. affected by plasminogen deficiency type 1
(PLGD-1). Considered an ultra-rare disease, PLGD-1 leads to reduced
plasminogen activity levels in the body, often resulting in
fibrinous lesions on various organs. Approximately 81% of patients
develop lesions on one or both eyes as their primary symptom;
however, lesions can develop throughout the body, potentially on
all organs with mucous membranes. Patients with PLGD-1 may require
lifelong treatment.
"We at Kedrion Biopharma appreciate our ongoing partnership with
Soleo Health, especially with our latest specialty pharmaceutical,
RYPLAZIM. We are confident that our continued collaboration will
further improve the lives of patients suffering from PLGD-1 to
ensure this essential medication reaches those who need it most,"
asserted Bob Rossilli, chief commercial officer of Kedrion
Biopharma.
"We take pride in being among the few selected specialty
pharmacy providers administering RYPLAZIM to PLGD-1 patients.
Complex conditions like PLGD-1 require our clinical excellence and
extensive knowledge to ensure patients receive appropriate access
to treatment while simplifying their complex care. We are thankful
for our relationship with Kedrion and the opportunity to make a
significant difference in these patients’ lives," explained Drew
Walk, chief executive officer of Soleo Health.
For more information about receiving RYPLAZIM therapy and
services through Soleo Health, contact the Company at phone
844.547.8600 or fax 380.257.2419.
About Soleo Health
Frisco, Texas-based Soleo Health is a leading national provider
of complex specialty pharmacy services administered in the home or
at alternate sites of care. Soleo Health’s interdisciplinary team
comprises highly experienced clinical pharmacists, registered
nurses, reimbursement specialists and patient care ambassadors
collaborating with its referring partners.
The Company optimizes patient access solutions and delivers
comprehensive services, leading to quantifiable clinical and
economic value, resulting in positive patient experiences. Soleo
Health has 26 pharmacy locations with national nursing coverage and
pharmacy licensure in 50 states and is accredited by URAC, ACHC
with Distinction in Rare Disease and Orphan Drugs and The Joint
Commission. Additionally, the Company operates more than 30
infusion centers throughout the U.S.
Visit www.soleohealth.com or connect with Soleo Health on
LinkedIn, Facebook and X for more
information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240506793284/en/
Susan Turkell, 303.766.4343, sturkell@soleohealth.com
RYPLAZIM Therapy Inquiries: 844.547.8600